CY1119352T1 - Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων - Google Patents

Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων

Info

Publication number
CY1119352T1
CY1119352T1 CY20171100940T CY171100940T CY1119352T1 CY 1119352 T1 CY1119352 T1 CY 1119352T1 CY 20171100940 T CY20171100940 T CY 20171100940T CY 171100940 T CY171100940 T CY 171100940T CY 1119352 T1 CY1119352 T1 CY 1119352T1
Authority
CY
Cyprus
Prior art keywords
diseases
treatment
pharmaceutical compositions
units
inflammatory disorders
Prior art date
Application number
CY20171100940T
Other languages
English (en)
Inventor
Nicolas Desroy
Bertrand Heckmann
Reginald Christophe Xavier Brys
Agnès Joncour
Christophe Peixoto
Xavier Bock
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CY1119352T1 publication Critical patent/CY1119352T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει ενώσεις σύμφωνα με τον Τύπο I: Όπου τα R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy και ο δείκτης a είναι όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αναφέρεται σε ενώσεις που αναστέλλουν την αυτοταξίνη (ΝΡΡ2 ή ΕΝΡΡ2), σε μεθόδους για την παραγωγή τους, σε φαρμακευτικές συνθέσεις που περιλαμβάνουν τις ίδιες και σε μεθόδους αγωγής δια της χρήσεως των ιδίων, για την προφύλαξη και/ή αγωγή νόσων που περιλαμβάνουν ινωτικές νόσους, υπερπλαστικές νόσους, φλεγμονώδεις νόσους, αυτοάνοσες νόσους, αναπνευστικές νόσους, καρδιαγγειακές νόσους, νευροεκφυλιστικές νόσους, δερματολογικές διαταραχές και/ή νόσους σχετιζόμενες με αφύσικη αγγειογένεση δια χορηγήσεως της ενώσεως της εφευρέσεως.
CY20171100940T 2013-03-14 2017-09-06 Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων CY1119352T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781174P 2013-03-14 2013-03-14
PCT/EP2014/054440 WO2014139882A1 (en) 2013-03-14 2014-03-07 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
CY1119352T1 true CY1119352T1 (el) 2018-02-14

Family

ID=50236198

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100940T CY1119352T1 (el) 2013-03-14 2017-09-06 Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων
CY20201100953T CY1123521T1 (el) 2013-03-14 2020-10-09 Νεες ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100953T CY1123521T1 (el) 2013-03-14 2020-10-09 Νεες ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων

Country Status (30)

Country Link
US (7) US8993590B2 (el)
EP (3) EP2970255B9 (el)
JP (2) JP6339595B2 (el)
KR (2) KR20210034098A (el)
CN (1) CN105143221B (el)
AR (1) AR095280A1 (el)
AU (3) AU2014231009B2 (el)
BR (1) BR112015020998B1 (el)
CA (1) CA2902103C (el)
CY (2) CY1119352T1 (el)
DK (2) DK3269716T3 (el)
ES (2) ES2638980T3 (el)
HK (2) HK1219730A1 (el)
HR (2) HRP20171219T1 (el)
HU (2) HUE051195T2 (el)
IL (2) IL240531B (el)
LT (2) LT2970255T (el)
MX (1) MX358342B (el)
MY (1) MY170260A (el)
NZ (1) NZ711202A (el)
PH (1) PH12015502055B1 (el)
PL (2) PL3269716T3 (el)
PT (2) PT3269716T (el)
RU (1) RU2675818C2 (el)
SG (1) SG11201507224RA (el)
SI (2) SI2970255T1 (el)
TW (2) TWI695002B (el)
UY (1) UY35437A (el)
WO (1) WO2014139882A1 (el)
ZA (1) ZA201505909B (el)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201914121YA (en) 2011-09-14 2020-03-30 Samumed Llc Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
HUE051195T2 (hu) 2013-03-14 2021-03-01 Galapagos Nv Új vegyületek és gyógyászati készítményeik gyulladásos rendellenességek kezelésére
JP6435323B2 (ja) 2013-06-19 2018-12-05 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規化合物及びその医薬組成物
EP3057649B1 (en) 2013-10-15 2020-12-02 Radux Devices, LLC Securing a medical device to a valve instrument
HUE057702T2 (hu) 2014-08-29 2022-05-28 Chdi Foundation Inc Szondák huntingtin fehérje képalkotáshoz
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
CN108472290A (zh) 2015-11-06 2018-08-31 萨穆梅德有限公司 治疗骨关节炎
WO2017192228A1 (en) * 2016-05-06 2017-11-09 Albert Einstein College Of Medicine, Inc. Pak1 inhibitors and uses thereof
PT3464285T (pt) 2016-06-01 2022-12-20 Biosplice Therapeutics Inc Processo para preparar n-(5-(3-(7-(3-fluorofenil)-3himidazo[4,5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida
AU2017345699A1 (en) 2016-10-21 2019-05-16 Samumed, Llc Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors
US10978722B2 (en) 2016-10-24 2021-04-13 Precision Combustion, Inc. Regenerative solid oxide stack
WO2018085865A1 (en) 2016-11-07 2018-05-11 Samumed, Llc Single-dose, ready-to-use injectable formulations
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
GB201710851D0 (en) 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
KR20200040262A (ko) * 2017-08-09 2020-04-17 갈라파고스 엔.브이. 섬유성 질병의 치료에 사용하기 위한 화합물 및 그의 약학 조성물
WO2019029620A1 (zh) * 2017-08-09 2019-02-14 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用
BR112020008425A2 (pt) 2017-11-15 2020-11-17 Galapagos N.V. compostos e composições farmacêuticas dos mesmos para uso no tratamento de doenças fibróticas
JP2021513551A (ja) * 2018-02-14 2021-05-27 スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドＳｕｚｈｏｕ Ｓｉｎｏｖｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． 複素環式化合物、その応用及びそれを含有する医薬組成物
AU2019272377B2 (en) * 2018-05-24 2022-03-10 Guangzhou Henovcom Bioscience Co., Ltd. Heteroaromatic compounds, pharmaceutical compositions and uses thereof
WO2019228403A1 (en) * 2018-05-29 2019-12-05 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
US10711000B2 (en) 2018-05-29 2020-07-14 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
EP4219452A1 (en) * 2018-07-27 2023-08-02 Mitsubishi Tanabe Pharma Corporation Novel 3,5-disubstituted pyridine and 3,5-disubstituted pyridazine derivatives and pharmaceutical use of same
GB201812861D0 (en) 2018-08-08 2018-09-19 Galapagos Nv Methods of administering therapy
MX2021004860A (es) 2018-10-29 2021-06-15 Boehringer Ingelheim Int Piridazinas novedosas.
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TW202110831A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
WO2021013833A1 (en) 2019-07-22 2021-01-28 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases
US11485727B2 (en) 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
EP3782997A1 (en) 2019-08-19 2021-02-24 Galapagos N.V. Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
JP7389238B2 (ja) 2019-09-06 2023-11-29 武漢人福創新薬物研発中心有限公司 ピリミジン化合物及びその調製方法
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
CN111004235A (zh) * 2019-11-29 2020-04-14 沈阳药科大学 一种ATX抑制剂Ziritaxestat的合成方法
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
EP4180430A4 (en) * 2020-07-09 2023-12-20 Suzhou Ark Biopharmaceutical Co., Ltd ATX INHIBITOR AND PRODUCTION METHOD THEREOF AND USE THEREOF
JP2023548181A (ja) * 2020-11-04 2023-11-15 四川海思科制▲薬▼有限公司 Ａｔｘ阻害剤の重水素化誘導体及びその応用
WO2022100727A1 (zh) 2020-11-16 2022-05-19 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途
WO2022167457A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022167445A1 (en) 2021-02-02 2022-08-11 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2023235871A2 (en) * 2022-06-03 2023-12-07 Seer, Inc. Systems, compositions, and methods relating to neurodegenerative diseases
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014818A (pt) * 1999-10-08 2002-06-18 Gruenenthal Gmbh Imidazo-3-il-aminas bicìclicas procedimento de preparação e medicamentos que contém como substância ativa pelo menos uma imidazo-3-il-amina bicìclica
ATE432282T1 (de) * 2003-04-23 2009-06-15 Schering Corp 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
WO2007149395A2 (en) 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8148369B2 (en) * 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
CA2757415C (en) 2009-04-02 2018-02-06 Merck Patent Gmbh Autotaxin inhibitors
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9000025B2 (en) * 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
WO2012166415A1 (en) * 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
HUE051195T2 (hu) 2013-03-14 2021-03-01 Galapagos Nv Új vegyületek és gyógyászati készítményeik gyulladásos rendellenességek kezelésére

Also Published As

Publication number Publication date
US9670204B2 (en) 2017-06-06
SI3269716T1 (sl) 2020-12-31
US8993590B2 (en) 2015-03-31
CN105143221A (zh) 2015-12-09
EP2970255B1 (en) 2017-08-02
KR20210034098A (ko) 2021-03-29
LT3269716T (lt) 2020-10-26
ES2638980T3 (es) 2017-10-24
HK1249507A1 (zh) 2018-11-02
EP3760630A1 (en) 2021-01-06
TWI749290B (zh) 2021-12-11
JP6339595B2 (ja) 2018-06-06
BR112015020998B1 (pt) 2022-10-18
TW201936604A (zh) 2019-09-16
AU2017286828A1 (en) 2018-01-18
SI2970255T1 (sl) 2017-12-29
PL2970255T3 (pl) 2017-10-31
AU2019204539B2 (en) 2021-01-21
HUE035966T2 (en) 2018-05-28
KR102231637B1 (ko) 2021-03-25
AR095280A1 (es) 2015-09-30
PT3269716T (pt) 2020-10-09
US11072611B2 (en) 2021-07-27
NZ711202A (en) 2019-04-26
US10526329B2 (en) 2020-01-07
US20160244443A1 (en) 2016-08-25
CA2902103A1 (en) 2014-09-18
PT2970255T (pt) 2017-09-05
HRP20201641T1 (hr) 2020-12-25
EP2970255A1 (en) 2016-01-20
SG11201507224RA (en) 2015-10-29
CA2902103C (en) 2021-09-21
US20150111872A1 (en) 2015-04-23
WO2014139882A1 (en) 2014-09-18
AU2019204539A1 (en) 2019-07-18
ZA201505909B (en) 2021-09-29
US9249141B2 (en) 2016-02-02
AU2017286828B2 (en) 2019-04-04
BR112015020998A2 (pt) 2017-07-18
PH12015502055A1 (en) 2016-01-18
HRP20171219T1 (hr) 2017-11-03
RU2675818C2 (ru) 2018-12-25
AU2014231009B2 (en) 2017-10-05
HUE051195T2 (hu) 2021-03-01
PH12015502055B1 (en) 2016-01-18
US20200239466A1 (en) 2020-07-30
US20170362227A1 (en) 2017-12-21
RU2015143430A (ru) 2017-04-18
IL256624B (en) 2019-09-26
IL240531B (en) 2018-01-31
AU2014231009A1 (en) 2015-09-10
PL3269716T3 (pl) 2021-02-08
DK3269716T3 (da) 2020-10-19
ES2824723T3 (es) 2021-05-13
CY1123521T1 (el) 2022-03-24
IL256624A (en) 2018-02-28
HK1219730A1 (zh) 2017-04-13
JP6517976B2 (ja) 2019-05-22
EP3269716A1 (en) 2018-01-17
UY35437A (es) 2014-10-31
US20230022534A1 (en) 2023-01-26
IL240531A0 (en) 2015-10-29
US10125132B2 (en) 2018-11-13
LT2970255T (lt) 2017-12-11
EP2970255B9 (en) 2018-09-19
US20140303140A1 (en) 2014-10-09
MX358342B (es) 2018-08-15
EP3269716B1 (en) 2020-09-16
MY170260A (en) 2019-07-13
TWI695002B (zh) 2020-06-01
MX2015011077A (es) 2015-10-29
CN105143221B (zh) 2017-06-09
JP2018135350A (ja) 2018-08-30
US20190169184A1 (en) 2019-06-06
DK2970255T3 (en) 2017-09-18
KR20150128995A (ko) 2015-11-18
TW201444835A (zh) 2014-12-01
JP2016512208A (ja) 2016-04-25

Similar Documents

Publication Publication Date Title
CY1119352T1 (el) Ενωσεις και φαρμακευτικες συνθεσεις αυτων για την αγωγη φλεγμονωδων διαταραχων
CY1124394T1 (el) Συνθεσεις τετραϋδροκινολινης ως αναστολεις βετ βρωμο-επικρατειων
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CR20150611A (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis por el virus de la hepatitis b
CY1123988T1 (el) Ενωση πυριδινης
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
CO2017006174A2 (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis
CO6480975A2 (es) Mimetico de smac
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
EA201691940A1 (ru) Новые соединения
BR112018003343A2 (pt) compostos heteroarila como inibidores de irak e usos dos mesmos
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
BR112018003812A2 (pt) compostos de heteroarila como inibidores de irak e usos dos mesmos
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
MX2017014035A (es) Formas solidas novedosas.
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
EA201700042A1 (ru) Соединения имидазопиридазина
CR20150649A (es) Derivados de nucleósidos 4´-azido,3´-desoxi-3´-fluoro sustituido
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme
DK2814495T3 (da) Fremgangsmåde til behandling af tarmsygdomme, der udviser mindst én inflammatorisk komponent
CY1122375T1 (el) Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer
CY1119666T1 (el) Φαρμακευτικες συνθεσεις
MX2016002043A (es) Imidazoles sustituidos como bloqueadores de canales de calcio tipo n.